Braveheart Inv Share News (BRH)

IN BRIEF: Braveheart buys 4 million Autins shares for GBP320,000

Braveheart Investment Group PLC - Dodworth, England-based investment company - Between Monday and Tuesday, buys a further 4.0 million shares in Autins Group PLC at an average price of 8 pence per share, for a total of GBP320,000. Following this, now holds 23% of the issued share capital of Autins.

Braveheart takes Autins stake to over 23pc

(Sharecast News) - Braveheart Investment Group announced a significant increase in its ownership stake in Autins Group on Wednesday.

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Braveheart to retain Paraytec after failing to find buyer

(Sharecast News) - Braveheart Investment Group updated the market on one of its key investments, Paraytec, on Monday, confirming that it had failed to find an appropriate buyer for the company.

TRADING UPDATES: Beowulf ups Vardar stake; Impellam buyout nears

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

IN BRIEF: Braveheart Investment to sell Phasefocus for GBP5 million

Braveheart Investment Group PLC - Dodworth, England-based investment company - Announces conditional sale of Phasefocus Holdings Ltd to analytics instrumentation company Bruker UK Ltd for GBP5 million. Once closing conditions are satisfied, Braveheart expects completion of the sale to occur in the first quarter of 2024. Consideration will be payable in cash and represent GBP17.74 per Phasefocus share. Braveheart currently holds 48.3% of Phasefocus's issued share capital. Estimates that it will receive total sale proceeds of approximately GBP2.1 million after expenses. Braveheart says board is still considering whether to use proceeds to continue support further investments in technology-based companies, or whether to redistribute the proceeds via a special dividend.

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

EARNINGS AND TRADING: abrdn Diversified Income to begin wind-down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Braveheart Investment firm gets first CX300 detector sales contract

(Alliance News) - Braveheart Investment Group PLC on Wednesday said its wholly-owned portfolio company Paraytec Ltd has secured its first commercial sales contract for the CX300 Optical Particle detector instrument.

IN BRIEF: Braveheart Investment investee Paraytec updates on CX300

Braveheart Investment Group PLC - Dodworth, England-based investment company - Investee company Paraytec Ltd updates on its work in the development of potential use cases for its rapid test instrument, CX300. Explains it has been successfully tested in the detection of adeno-associated viruses, which are used in gene therapy. Notes this is important because virus-like particles such as adeno-associated viruses are used to encapsulate the new gene and deliver it into the body. Points out the target is to market the CX300 for use by all gene therapy manufacturers for in-process assessment of the quality of their adeno-associated virus products during research, development and, in due course, manufacturing.

Braveheart upbeat on investee's brain research breakthrough

(Sharecast News) - Braveheart Investment Group updated the market on the progress of its investee company Kirkstall on Friday, including a recent breakthrough in the study of the human blood-brain barrier and its interaction with brain cancer.

IN BRIEF: Braveheart Investment investee Kirkstall develops new model

Braveheart Investment Group PLC - Dodworth, England-based investment company - Updates on Kirkstall Ltd, a company within its investment portfolio. Says Kirkstall, in conjunction with the Biomedical Ultrasonics, Biotherapy & Biopharmaceutical Laboratory within the Institute of Biomedical Engineering at the University of Oxford, has developed an "organ on a chip" model of a milli-fluidic system, human blood-brain barrier which has been used to map the interaction between the blood-brain barrier and brain cancer. Explains this is the first time a dynamic milli-fluidic model has been developed where the interactions between the blood-brain barrier and medulloblastoma brain cancer spheroids have been demonstrated.

Braveheart invests GBP150,000 in Phasefocus for cancer-focused assay

(Alliance News) - Braveheart Investment Group PLC on Monday said it has invested more in Phasefocus Holdings Ltd, a Sheffield-based company that develops products that quantify and compare dynamic live cell behaviour.

TRADING UPDATES: Limitless Earth loss widens; Black Sea NAV rises

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days